 "Rossari Biotech IPO off to good start, subscribed nearly 60% on first day")
Rossari Biotech’s initial public offering (IPO) was subscribed nearly 60 per cent on Monday, the first day of the issue.
The 8.17-million share offering has so far received bids for 4.9 million shares, stock exchange data showed. The institutional investor portion of the IPO has been subscribed 41 per cent, the wealthy investor portion has received 11 per cent subscription, while the retail investor portion has been covered 92 per cent. The specialty chemicals company on Friday had allotted shares worth nearly Rs 150 crore to anchor investors.
Market players said the initial response to the IPO is encouraging. Rossari is the first IPO to hit the domestic markets since early-March.
The pandemic and subsequent lockdowns have forced many firms to hold back their IPO plans despite clearances. Rossari had intended to launch its IPO in March, however, decide to postpone the plan.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%